Abstract
Therapeutic re-challenge is currently a debated issue in the field of multiple myeloma (MM), given the recent availability of several new drugs and combinations. However, very few specific evidences are available about bortezomib re-use at first relapse. This multicenter, observational, retrospective study enrolled 134 MM patients with significant response after bortezomib-based frontline regimens and who had received a first salvage treatment containing bortezomib at relapse. The overall response rate was 71%, including 40% partial responses, 24% very good partial responses, and 7% complete responses. Re-treatment was well-tolerated, with no significant new or unexpected toxicities observed. The median duration of second progression-free survival (PFS) was 15 months, while median PFS2 was 55 months. With a median follow-up of 56 months, overall survival was 94 months for the entire series, without significant differences between patients undergoing or not undergoing transplant procedures. This real-life survey indicates that re-treatment including bortezomib as a first salvage therapy could be still considered in MM patients achieving durable response after initial exposure to bortezomib.
| Original language | English |
|---|---|
| Journal | Annals of Hematology |
| DOIs | |
| Publication status | Accepted/In press - Jan 1 2018 |
Fingerprint
Keywords
- Bortezomib
- First relapse
- Myeloma
- Re-treatment
- Salvage therapy
ASJC Scopus subject areas
- Hematology
Cite this
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study). / Musto, Pellegrino; Simeon, Vittorio; Cascavilla, Nicola; Falcone, Antonietta; Petrucci, Maria Teresa; Cesini, Laura; Di Raimondo, Francesco; Conticello, Concetta; Ria, Roberto; Catalano, Lucio; Salvatore, Dalila; Mastrullo, Lucia; Gagliardi, Alfredo; Villani, Oreste; Pietrantuono, Giuseppe; D’Arena, Giovanni; Mansueto, Giovanna; Bringhen, Sara; Genuardi, Mariella; Di Renzo, Nicola; Reddiconto, Giovanni; Fragasso, Alberto; Caravita, Tommaso; Scapicchio, Daniele; Marziano, Gioacchino; Boccadoro, Mario; Mangiacavalli, Silvia; Corso, Alessandro.
In: Annals of Hematology, 01.01.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)
AU - Musto, Pellegrino
AU - Simeon, Vittorio
AU - Cascavilla, Nicola
AU - Falcone, Antonietta
AU - Petrucci, Maria Teresa
AU - Cesini, Laura
AU - Di Raimondo, Francesco
AU - Conticello, Concetta
AU - Ria, Roberto
AU - Catalano, Lucio
AU - Salvatore, Dalila
AU - Mastrullo, Lucia
AU - Gagliardi, Alfredo
AU - Villani, Oreste
AU - Pietrantuono, Giuseppe
AU - D’Arena, Giovanni
AU - Mansueto, Giovanna
AU - Bringhen, Sara
AU - Genuardi, Mariella
AU - Di Renzo, Nicola
AU - Reddiconto, Giovanni
AU - Fragasso, Alberto
AU - Caravita, Tommaso
AU - Scapicchio, Daniele
AU - Marziano, Gioacchino
AU - Boccadoro, Mario
AU - Mangiacavalli, Silvia
AU - Corso, Alessandro
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Therapeutic re-challenge is currently a debated issue in the field of multiple myeloma (MM), given the recent availability of several new drugs and combinations. However, very few specific evidences are available about bortezomib re-use at first relapse. This multicenter, observational, retrospective study enrolled 134 MM patients with significant response after bortezomib-based frontline regimens and who had received a first salvage treatment containing bortezomib at relapse. The overall response rate was 71%, including 40% partial responses, 24% very good partial responses, and 7% complete responses. Re-treatment was well-tolerated, with no significant new or unexpected toxicities observed. The median duration of second progression-free survival (PFS) was 15 months, while median PFS2 was 55 months. With a median follow-up of 56 months, overall survival was 94 months for the entire series, without significant differences between patients undergoing or not undergoing transplant procedures. This real-life survey indicates that re-treatment including bortezomib as a first salvage therapy could be still considered in MM patients achieving durable response after initial exposure to bortezomib.
AB - Therapeutic re-challenge is currently a debated issue in the field of multiple myeloma (MM), given the recent availability of several new drugs and combinations. However, very few specific evidences are available about bortezomib re-use at first relapse. This multicenter, observational, retrospective study enrolled 134 MM patients with significant response after bortezomib-based frontline regimens and who had received a first salvage treatment containing bortezomib at relapse. The overall response rate was 71%, including 40% partial responses, 24% very good partial responses, and 7% complete responses. Re-treatment was well-tolerated, with no significant new or unexpected toxicities observed. The median duration of second progression-free survival (PFS) was 15 months, while median PFS2 was 55 months. With a median follow-up of 56 months, overall survival was 94 months for the entire series, without significant differences between patients undergoing or not undergoing transplant procedures. This real-life survey indicates that re-treatment including bortezomib as a first salvage therapy could be still considered in MM patients achieving durable response after initial exposure to bortezomib.
KW - Bortezomib
KW - First relapse
KW - Myeloma
KW - Re-treatment
KW - Salvage therapy
UR - http://www.scopus.com/inward/record.url?scp=85055693033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055693033&partnerID=8YFLogxK
U2 - 10.1007/s00277-018-3524-1
DO - 10.1007/s00277-018-3524-1
M3 - Article
AN - SCOPUS:85055693033
JO - Annals of Hematology
JF - Annals of Hematology
SN - 0939-5555
ER -